Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.
We will be presenting at the BofA/ML, UBS, Jefferies and Goldman Sachs conferences.
Keep an eye on our events section for dates and times.
Why the Study of Cell Signaling is Critical to Improving Cancer Care
Merrimack co-founder and MIT/Harvard professor, Michael Yaffe, recently published a perspective piece on the critical need to move beyond genomics to study the role of signaling networks in cancer. Learn more about his perspective here.
Merrimack’s pipeline was on display at the annual AACR conference: we presented two oral presentations and five poster presentations
At the 2013 American Association for Cancer Research annual conference, held in Washington, D.C., we had the opportunity to show off our latest research touching on five of the six novel therapeutics we’re advancing in the clinic.
Our Heroes
Merrimack is delighted to announce its alliance with the Pancreatic Cancer Action Network, an organization dedicated to advancing research, supporting patients and creating hope for those affected by pancreatic cancer.
Using Nanotechnology to Improve Treatment for Pancreatic Cancer
MM-398, an exploratory new medicine for pancreatic cancer, is founded on a technology that allows us to increase a tumor cell's exposure to chemotherapy. Learn more about MM-398.
Breaking down the science of systems biology
Professor Peter Sorger of Harvard Medical School discusses the science of systems biology and its potential impact on cancer care.
New Insights in Cancer: A Novel Therapy with the Potential to Treat a Central Node in Cancer
MM-121 is a novel signaling inhibitor being developed by Merrimack and Sanofi Oncology across multiple cancer indications, including breast, lung and ovarian cancer. Our research suggests that MM-121’s target, HER3, could play a substantial role in the growth and survival of cancer. Learn more about MM-121 and its clinical program here.